Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) has reported E.P.S. of $1.01 for its third fiscal quarter (ending September 30) versus $0.32 for the same period a year ago — an increase of 216%. Relative to the consensus estimate of $0.69, this was a premium of $0.32. For the latest four quarters through September 30, E.P.S. were $2.80 compared to $1.59 a year ago — an increase of 76%.
Recent Price Action
On 11/8/23, Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) stock declined by -1.3%, closing at $45.42. Relative to the market the stock has been exceptionally strong over the last nine months and is unchanged during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, AMPH is expected to continue to be a major Value Builder.
Amphastar Pharmaceuticals has a current Value Trend Rating of C (High Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Amphastar Pharmaceuticals has a poor Appreciation Score of 28 but a very high Power Rating of 93, producing the High Neutral Value Trend Rating.
Rating Review
In light of this encouraging new earnings information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment